Cover Image
市場調查報告書

肌少症 : 開發平台分析

Sarcopenia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213093
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
肌少症 : 開發平台分析 Sarcopenia - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 61 Pages
簡介

所謂肌少症,定義為老齡化伴隨的肌力的量、功能低下。主要的症狀為,肥胖和步行、移動障礙,肌力不足,呼吸困難等。主要的治療方法,有藥物療法和荷爾蒙置換療法等。

本報告提供全球各國的肌少症治療用的開發中產品的開發情形相關分析、產品開發與上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊、為您概述為以下內容。

目錄

簡介

  • 分析範圍

肌少症概要

治療藥的開發

  • 肌少症的開發中產品:概要
  • 肌少症的開發中產品:比較分析

各企業開發中的肌少症治療藥

大學/研究機關研究中的肌少症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

肌少症治療藥:開發中的產品一覽(各企業)

肌少症治療藥:研究中的產品一覽(各大學/研究機關)

肌少症開發治療藥的企業

  • GlaxoSmithKline Plc
  • Myos Corporation
  • Neurotune AG
  • Novartis AG
  • PolyNovo Limited
  • PsiOxus Therapeutics Limited
  • Regeneron Pharmaceuticals, Inc.
  • 大日本住友製藥

肌少症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AOD-9604
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ARM-210
  • bimagrumab
  • BIO-101
  • BIO-103
  • Espindolol
  • NEP-28
  • NT-1654
  • 肌肉骨骼障礙用蛋白質
  • 肌少症的基因改造型蛋白質
  • S-107
  • 肌少症的、惡病質 Furin 抑制劑
  • 慢性風濕病、肌少症、惡病質用 JAK3 抑制劑
  • trevogrumab

肌少症治療藥:開發中產品的最新趨勢

肌少症治療藥:開發暫停的產品

肌少症治療藥:開發中止的產品

肌少症相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8277IDB

Summary

Global Markets Direct's, 'Sarcopenia - Pipeline Review, H2 2016', provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sarcopenia
  • The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects
  • The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarcopenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sarcopenia Overview
  • Therapeutics Development
    • Pipeline Products for Sarcopenia - Overview
    • Pipeline Products for Sarcopenia - Comparative Analysis
  • Sarcopenia - Therapeutics under Development by Companies
  • Sarcopenia - Therapeutics under Investigation by Universities/Institutes
  • Sarcopenia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Sarcopenia - Products under Development by Companies
  • Sarcopenia - Products under Investigation by Universities/Institutes
  • Sarcopenia - Companies Involved in Therapeutics Development
    • Atara Biotherapeutics, Inc.
    • Biophytis SAS
    • GlaxoSmithKline Plc
    • MYOS RENS Technology Inc.
    • Neurotune AG
    • Novartis AG
    • PsiOxus Therapeutics Limited
    • Regeneron Pharmaceuticals, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Sarcopenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-4210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • espindolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEP-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Sarcopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sarcopenia - Dormant Projects
  • Sarcopenia - Discontinued Products
  • Sarcopenia - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th
      • Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob
      • Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity
      • Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
      • Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia
      • Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sarcopenia, H2 2016
  • Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Sarcopenia - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Sarcopenia - Pipeline by Biophytis SAS, H2 2016
  • Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Sarcopenia - Pipeline by MYOS RENS Technology Inc., H2 2016
  • Sarcopenia - Pipeline by Neurotune AG, H2 2016
  • Sarcopenia - Pipeline by Novartis AG, H2 2016
  • Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Sarcopenia - Dormant Projects, H2 2016
  • Sarcopenia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Sarcopenia, H2 2016
  • Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top